MannKind Corp’s Afrezza Won Recommendations from U.S. Advisory Panel

MannKind Corp’s Afrezza Won Recommendations from U.S. Advisory Panel

After long-waiting for the approval of inhaled diabetes treatment drug, Afrezza, MannKind Corp. finally got recommendation from U. S. advisory panel. The panel of Food and Drug Administration (FDA) advisers has voted 13 in favor of recommending the drug for treating Type 1 and Type 2 diabetes.

Earlier, two times rejection of the MannKind's inhaled diabetes drug in 2011 and the release of Pfizer Inc's inhaled diabetes drug, Exubera, in 2006, caused the company to witness steep decrease in its shares from 21.70 to $1.60. But, the Pfizer Inc's Exubera later on faced setback as the drug showed increased risk of lung cancer because the insulin was directly deposited in the lungs.

Despite of recommendation from advisory panel, FDA raised the same concern claiming the Afrezza may cause lung function. Moreover, they added that the drug contains some missing information from the study conducted on Type 1 patients.

Alfred Mann, 88-year-old founder, chairman, chief executive officer and largest shareholder of the Company, said his company feels pleased on the approval recommendation of the Afrezza.

Diabetes is a major health problem in the U. S. and the development of the novel drug would prove successful in treating patients without following insulin injections, said Alfred.

According to statistical report by the Centers for Disease Control and Prevention (CDC), about 26 million people were suffering with diabetes in U. S. in 2010 and declared the disease as the seventh-leading cause of death in the U. S.

About 90% to 95% of deaths in U. S. are caused by Type 2 diabetes, according to sources. The average estimate by three analysts has revealed that the approval of the drug by the FDA, which will be declared by April 15, is expected to generate revenue of $534 million in 2018.


FrenchTribune Specials

South Korea to infuse $13 billion to boost growth

The government in South Korea has announced that it will infuse more than 15 trillion won or $13 billion on Thursday in order to boost economic growth as the MERS virus affects the economic growth.

The government announced a financial packageincluding a supplementary budget in order to boost growth as its economy faces pressure.South...

Most Popular

PornHub aiming to riase $3.4M in crowdfunding

Pornographic website, Pornhub has said that it is aiming...

Rape prevention program dramatically reduces sexual assaults: Study

A Canadian study at three Canadian universities has...

Serengeti Captured Phenomenally by 225 Hidden Cameras

The Serengeti snapshot project involving the setting up...

Researchers using Minecraft game to train robots

A team of researchers at the Brown University have found...

Poll

Can Greece Come out of Economic Problems: